These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 18490499)

  • 1. An improved approach for confirmatory phase III population pharmacokinetic analysis.
    Hu C; Zhou H
    J Clin Pharmacol; 2008 Jul; 48(7):812-22. PubMed ID: 18490499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confirmatory analysis for phase III population pharmacokinetics.
    Hu C; Zhang J; Zhou H
    Pharm Stat; 2011; 10(1):14-26. PubMed ID: 20041468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments.
    Graham G; Aarons L
    Stat Med; 2006 Dec; 25(23):4004-19. PubMed ID: 16463254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2009; 19(1):174-89. PubMed ID: 19127474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A hybrid Bayesian-frequentist approach to evaluate clinical trial designs for tests of superiority and non-inferiority.
    Shao Y; Mukhi V; Goldberg JD
    Stat Med; 2008 Feb; 27(4):504-19. PubMed ID: 17854052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
    Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
    Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerations.
    Grouin JM; Coste M; Bunouf P; Lecoutre B
    Stat Med; 2007 Nov; 26(27):4914-24. PubMed ID: 17559054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.
    Ette EI; Williams PJ; Lane JR
    Ann Pharmacother; 2004 Dec; 38(12):2136-44. PubMed ID: 15507495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of pharmacokinetic sampling schedules in clinical phase I trials: a use of Kullback-Leibler information.
    Yafune A; Ishiguro M
    Stat Med; 2001 Apr; 20(7):1033-49. PubMed ID: 11276034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
    Kimani PK; Stallard N; Hutton JL
    Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective.
    Wade JR; Edholm M; Salmonson T
    AAPS J; 2005 Oct; 7(2):45. PubMed ID: 16353906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline.
    Bolland K; Whitehead J; Cobo E; Secades JJ
    Pharm Stat; 2009; 8(2):136-49. PubMed ID: 18637642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of population pharmacokinetics to the drug development process.
    Jackson KA; Rosenbaum SE
    Drug Dev Ind Pharm; 1998 Dec; 24(12):1155-62. PubMed ID: 9876572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality.
    Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B
    Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.
    Bria E; Gralla RJ; Raftopoulos H; Cuppone F; Milella M; Sperduti I; Carlini P; Terzoli E; Cognetti F; Giannarelli D
    Lung Cancer; 2009 Jan; 63(1):50-7. PubMed ID: 18565615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary.
    Lefebvre JL; Ang KK;
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1293-303. PubMed ID: 19306746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
    Wang DD; Zhang S; Zhao H; Men AY; Parivar K
    J Clin Pharmacol; 2009 Sep; 49(9):1012-24. PubMed ID: 19620385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
    Resche-Rigon M; Zohar S; Chevret S
    Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.